創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 20/02/18 | GEM151 | anti-GM-CSF monoclonal antibody | Rheumatoid arthritis & multiple new indications* （see note） | i.v. | Antibody | Preclinical （ready for IND-enabling studies） | GM-CSF is a key player in inflammation and autoimmunity. GEM151 is a fully human monoclonal antibody generated by single B cell cloning and has superior affinity (Kd: 7.3 X 10 -11 M) compared to competitors. Neutralizing activities were confirmed by four different functional assays. *cytokine release syndrome., GvHD, multiple sclerosis/neuroinflammation, Kawasaki disease |
問合せ |
| 20/02/12 | GEM150 | Melanocortin 4 & 5 agonist | Obesity | Oral | Peptide | Preclinical | A pro-drug of the cyclic peptide (BL3020-1) which is a melanocortin 4 & 5 agonist showing good permeability in the gut and BBB and great reduction in food consumption and body weight gain in mice. The pro-drug did not show aggregation which BL3020-1 did. Currently the pro-drug is being optimized. | 問合せ |
| 20/01/29 | GEM149 | PKC modulator | Alzheimer disease | Oral, Intra- nasal | Small molecule | Phase 1 | Up-regulates production of α-secretase which cleaves the amyloid precursor protein, APP, into a harmless soluble form, sAPP-α, which is non-neurotoxic and limits the formation of amyloid plaques. | 問合せ |
| 20/01/29 | GEM148 | CCR5 inhibition | HIV | i.v. | Nucleic acid | Preclinical | GEM148 is a nanoencapsulation of proprietary, synthetic CCR5-siRNA targeted to knock-down and eliminate HIV-1 in chronic HIV patients as well as prevent HIV-1 infection in naïve patients and re-infection in acutely-infected patients. | 問合せ |
| 20/01/29 | GEM147 | Insulin | Diabetes | Oral | Peptide | Preclinical | GEM147 is a nanoencapsulation of insulin in biodegradable polymer nanospheres. Nanoencapsulation protects insulin during stomach passage. In vivo, statistically significant reduction in blood glucose was seen in diabetic rats with oral GEM147 within 30 minutes. | 問合せ |
| 20/01/29 | GEM146 | VD Receptor | Prostate cancer, Autoimmune diseases | i.v. | Small molecule | Preclinical | GEM146 is a nanosomal formulation of a nontoxic Vitamin D3 analog. In vivo studies have shown strong anticancer effects of GEM146 against Hormone Refractory Prostate Cancer xenografts in nude mice at doses approximately 6.5 times less than the parent hormone, without significant toxicity. | 問合せ |
| 20/01/29 | GEM145 | 5-HT | Chemotherapy Induced Nausea and Vomiting （CINV) | Oral | Small molecule | Phase 2/3 | Acute vomiting was blocked effectively by 5-HT3 anti-emetics plus the adjuvant Emend® but no benefits were observed in terms of the incidence of nausea . Phase 2/3 clinical trial on GEM145 as an adjuvant to conventional 5-HT3 anti-emetics was completed (more than 600 cancer patients). All doses of GEM145 significantly reduced acute nausea severity compared to the placebo (p=0.003). | 問合せ |
| 20/01/29 | GEM144 | PKC modulator plus HDAC inhibitor | HIV Latency | i.v., Oral | Small molecule | Phase 2a | GEM144 is a nanoencapsulation of PKC modulators plus HDAC inhibitor in targeted, pegylated phospholipid nanosomes for improved therapeutic index. Activates HIV from latent reservoirs so that HIV can be eradicated from the body by antiviral therapy and/or immune system. |
問合せ |
| 20/01/29 | GEM143 | CB1, CB2, 5-HT1a | Multiple Sclerosis（MS), Opioid addiction, Chemotherapy induced Peripheral Neuropathic Pain（CIPNP), and Epilepsy | Oral | Small molecule | Preclinical | GEM143 is a nanoencapsulation of the API in biodegradable polymer nanospheres for improved oral bioavailability. MS: The API has multiple actions on key molecular neuroinflammation and neurodegeneration targets, with highly effective in vitro and in vivo bioactivities. Opioid addiction: The API is not an opioid and has been shown to alleviate cue-induced opioid addiction behaviors and allosterically modulate the μ and δ-opioid receptors. CIPNP: Nanoencapsulation is being used to protect the API during the stomach passage. Epilepsy: The API is an effective anti-convulsant with a specificity more comparable to drugs clinically effective in major seizures. |
問合せ |
| 20/01/20 | GEM142 | Nrf2 Activator | COPD and Diabetic kidney disease | Oral | Small molecule | Phase 1 | A novel Nrf2 activator. Inhibited airway inflammation to a similar degree as roflumilast in a mouse smoke exposure model. Improved urinary albumin/creatinine ratio in STZ-induced rat diabetic model (Type I) and KK-Ay mouse (Type II) and inhibited damage of the renal tissues. Synergistic effects by combination with losartan on urinary albumin/creatinine ratio were noted in KK-Ay mice. No adverse events were seen in multiple dose phase 1 study even at 1000 mg/man/day. | 問合せ |